StrokeGuard
Emergency neuroprotection in acute ischemic stroke (pre-hospital)
Pre-clinicalActive
Key Facts
Indication
Emergency neuroprotection in acute ischemic stroke (pre-hospital)
Phase
Pre-clinical
Status
Active
Company
About NeuraStasis
NeuraStasis is pioneering a novel neuroprotective device, StrokeGuard, to address the critical, untreated time gap between stroke onset and hospital arrival. The company's technology employs a closed-loop, AI-driven system that non-invasively stimulates the trigeminal nerve to increase cerebral blood flow, aiming to slow neuronal death during transport. This approach is modeled on the successful deployment paradigm of cardiac AEDs, targeting placement in ambulances and public facilities. If successful, StrokeGuard could transform pre-hospital stroke care by providing the first emergency intervention to 'buy time' for patients awaiting definitive treatment.
View full company profile